Clinical uses of melatonin: evaluation of human trials on cancer treatment.
Melatonin and cancer treatment
Keywords:
melatonin, cancer therapy, anticancer drugs
Abstract
Melatonin is a molecule with numerous properties, which are applicable to the treatment of different types of cancers. Experimental in vitro and in vivo studies conducted with human cancer cells or animal models of carcinogenesis, have shown that melatonin enhances apoptosis and inhibits cell proliferation of several human cancer cells, reduces tumor growth rate and its metastases, reduces the side effects of chemotherapy and radiotherapy, decreases the resistance to standard cancer treatments, and potentiates the therapeutic effects of other conventional therapies. These satisfactory results obtained from “bench” need to be studied in clinical trials to verify whether they are applicable to “bedside”. In this article we review the clinical trials carried out in the last 25 years which are focused on the therapeutic use of melatonin in cancer treatment. We conclude that melatonin is an effective adjuvant drug to practically any conventional cancer therapy since it is capable of improving the quality of life of patients, by normalizing sleep and alleviating general symptoms associated with tumor disease and treatment such as pain, asthenia, anorexia, etc. In the particular case of hormone-dependent breast cancer, melatonin's antiestrogenic properties make this indoleamine ideally suited for use in association with other synthetic anti-estrogen agents, as melatonin increases their efficacy while reducing their undesirable effects. Furthermore, melatonin could be an appropriate co-treatment for preventive treatment of breast cancer in people with elevated risk for this kind of neoplasia.
References
1. Lerner AB, Case JD, Takahashi Y (1960) Isolation of melatonin and 5- methoxyindole-3-acetic acid from bovine pineal glands. J. Biol. Chem. 235: 1992-1997.
2. Hardeland R (2008) Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol. Life Sci. 65 (13): 2001-2018.
3. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ (2012) Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin. Investig. Drugs 21: 819-831.
4. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Rueda N (2012) Breast cancer therapy based on melatonin. Recent Pat. Endocr. Metab. Immune Drug Discov. 6: 108-116.
5. Hill SM, Hill SM, Blask DE, Xiang S, Yuan L, Mao L, Dauchy RT, Dauchy EM, Frasch T, Duplesis T (2011) Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J. Mammary Gland Biol. Neoplasia 16: 235-245.
6. Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K (2017) Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int. J. Mol. Sci. 18 (4) pii: E843. doi: 10.3390/ijms18040843.
7. Talib WH (2018) Melatonin and cancer hallmarks. Molecules 23 (3) pii: E518. doi: 10.3390/molecules23030518.
8. Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Najafi M, Sahebkar A (2019) Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. J. Cell Physiol. 234: 5613-5627.
9. Najafi M, Salehi E, Farhood B, Nashtaei MS, Hashemi Goradel N, Khanlarkhani N, Namjoo Z, Mortezaee K (2019) Adjuvant chemotherapy with melatonin for targeting human cancers: A review. J. Cell Physiol. 234: 2356-2372.
10. Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Salehi E, Nashtaei MS, Mirtavoos-Mahyari H, Motevaseli E, Shabeeb D, Musa AE, Najafi M (2019) Melatonin as an adjuvant in radiotherapy for radioprotection and radio-sensitization. Clin. Transl. Oncol. 21: 268-279.
11. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ (2010) Basic mechanisms involved in the anti-cancer effects of melatonin. Curr. Med. Chem. 17: 4462-4481.
12. Proietti S, Cucina A, Reiter RJ, Bizzarri M (2013) Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol. Life Sci. 70: 2139-2157.
13. Bondy SC, Campbell A (2018) Mechanisms Underlying Tumor Suppressive Properties of Melatonin. Int. J. Mol. Sci. 19 (8). pii: E2205. doi: 10.3390/ ijms19082205.
14. Lavastine L, Malméjac J (1939) Glande Pinéale. In: Traité de Physiologie Normale et Pathologique (Tome IV). Eds. Roger GH and Binet L. (Masson et Cie, Paris), pp 607-690.
15. Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ (2010) Clinical uses of melatonin: evaluation of human trials. Curr. Med. Chem. 17: 2070-2095.
16. Sánchez-Barceló EJ, Mediavilla MD, Reiter RJ (2011) Clinical uses of melatonin in pediatrics. Int. J. Pediatr. 2011: 892624. doi:10.1155/2011/892624.
17. Sanchez-Barcelo EJ, Rueda N, Mediavilla MD, Martinez-Cue C, Reiter RJ (2017) Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders. Curr. Med. Chem. 24: 3851-3878.
18. Cos S, Sánchez-Barceló EJ (2000). Melatonin and mammary pathological growth. Front. Neuroendocrinol. 21: 133-170.
19. Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C, Sánchez-Barceló EJ (2006). Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int. J. Cancer 118: 274-278.
20. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ (2010). Basic mechanisms involved in the anti-cancer effects of melatonin. Curr. Med. Chem. 17: 4462-4481.
21. Bizzarri M, Proietti S, Cucina A, Reiter RJ (2013) Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin. Ther. Targets 17: 1483-1496.
22. Onseng K, Johns NP, Khuayjarernpanishk T, Subongkot S, Priprem A, Hurst C, Johns J (2017) Beneficial effects of adjuvant melatonin in minimizing oral mucositis complications in head and neck cancer patients receiving concurrent chemoradiation. J. Altern. Complement Med. 23: 957-963.
23. Abdel Moneim AE, Guerra-Librero A, Florido J, Shen YQ, Fernández-Gil B, Acuña-Castroviejo D, Escames G (2017) Oral mucositis: melatonin gel an effective new treatment. Int. J. Mol. Sci. 18 (5) pii: E1003. doi: 10.3390/ijms18051003.
24. Su SC, Ho YC, Liu YF, Reiter RJ, Chou CH, Yeh CM, Lee HL, Chung WH, Hsieh MJ, Yang SF (2017) Association of melatonin membrane receptor1A/1B gene polymorphisms with the occurrence and metastasis of hepatocellular carcinoma. Oncotarget 8: 85655-85669.
25. Mortezaee K (2018) Human hepatocellular carcinoma: Protection by melatonin. J. Cell Physiol. 233: 6486-6508.
26. Prieto-Domínguez N, Ordóñez R, Fernández A, Méndez-Blanco C, Baulies A, Garcia-Ruiz C (2016) Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J. Pineal Res. 61: 396-407.
27. Prieto-Domínguez N, Méndez-Blanco C, Carbajo-Pescador S, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL (2017) Melatonin enhances enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy. Oncotarget 8: 91402-91414.
28. Lin S, Hoffmann K, Gao C, Petrulionis M, Herr I, Schemmer P (2017) Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. J. Pineal Res. 62 (3) doi: 10.1111/jpi.12398.
29. Yan JJ, Shen F, Wang K, Wu MC (2002) Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat Dis. Int. 1: 183-186.
30. Sakatani A, Sonohara F, Goel A (2019) Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis 40 (3): 422-431.doi.10.1093/carcin/bgy186.
31. Lee JH, Yun CW, Han YS, Kim S, Jeong D, Kwon HY, Kim H, Baek MJ, Lee SH (2018) Melatonin and 5-fluorouracil co-suppress colon cancer stem cells by regula-ting cellular prion protein-Oct4 axis. J. Pineal Res. 65: e12519. doi: 10.1111/jpi.12519.
32. Wang Q, Sun Z, Du L, Xu C, Wang Y, Yang B, He N, Wang J, Ji K, Liu Y, Liu Q. (2018) Melatonin sensitizes human colorectal cancer cells to γ-ray ionizing radiation in vitro and in vivo. Int. J. Mol. Sci. 19: pii: E3974. doi: 10.3390/ijms19123974.
33. Lee JH, Yoon YM, Han YS, Yun CW, Lee SH (2018) Melatonin promotes apoptosis of oxaliplatin-resistant colorectal cancer cells through inhibition of cellular prion protein. Anticancer Res. 38: 1993-2000.
34. Wei JY, Li WM, Zhou LL, Lu QN, He W (2015) Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. J. Pineal Res. 58: 429-438.
35. Yun CW, Kim S, Lee JH, Lee SH (2018) Melatonin promotes apoptosis of colorectal cancer cells via superoxide-mediated ER stress by inhibiting cellular prion protein expression. Anticancer Res. 38: 3951-3960.
36. Lissoni P (2007). Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol. Biol. 55: 201-204.
37. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P (2003) Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 23: 1951-1954.
38. Asghari MH, Moloudizargari M, Ghobadi E, Fallah M, Abdollahi M (2017) Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer. Life Sci. 185: 38-45.
39. Song J, Ma SJ, Luo JH, Zhang H, Wang RX, Liu H, Li L, Zhang ZG, Zhou RX (2018) Melatonin induces the apoptosis and inhibits the proliferation of human gastric cancer cells via blockade of the AKT/MDM2 pathway. Oncol. Rep. 39: 1975-1983.
40. Michl P, Gress TM (2013) Current concepts and novel targets in advanced pancreatic cancer. Gut 62: 317-326.
41. Jaworek J, Leja-Szpak A, Nawrot-Porąbka K, Szklarczyk J, Kot M, Pierzchalski P, Góralska M (2017) Effects of melatonin and its analogues on pancreatic inflammation, enzyme secretion, and tumorigenesis. Int. J. Mol. Sci. 18: pii: E1014. doi: 10.3390/ijms18051014.
42. Tamtaji OR, Mirhosseini N, Reiter RJ, Behnamfar M, Asemi Z (2019) Melatonin and pancreatic cancer: Current knowledge and future perspectives. J. Cell Physiol. 234: 5372-5378.
43. Li W, Wu J, Li Z, Zhou Z, Zheng C, Lin L, Tan B, Huang M, Fan M (2016) Melatonin induces cell apoptosis in Mia PaCa-2 cells via the suppression of nuclear factor-κB and activation of ERK and JNK: A novel therapeutic implication for pancreatic cancer. Oncol. Rep. 36: 2861-2867.
44. Fang Z, Jung KH, Yan HH, Kim SJ, Rumman M, Park JH, Han B, Lee JE, Kang YW, Lim JH, Hong SS (2018) Melatonin synergizes with sorafenib to suppress pancreatic cancer via melatonin receptor and PDGFR-β/STAT3 pathway. Cell Physiol. Biochem. 47: 1751-1768.
45. Sigurdardottir LG, Markt SC, Rider JR, et al. (2015) Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur. Urol. 67: 191-194.
46. Tay SY, Huang SP, Bao BY, Wu MT (2016) Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study. Sci. Rep. 6: 29606. doi: 10.1038/srep29606.
47. Liu VWS, Yau WL, Tam CW, Yao KM & Shiu SYW (2017) Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-κB) activation and NF-κB activator-induced AR-V7 expression in prostate cancer cells: potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) therapy. Int. J. Mol. Sci. 18 (6): 1130. doi: 10.3390/ijms18061130.
48. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E (2012) Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials. Integr. Cancer Ther. 11: 293-303.
49. Zhao M, Wan J, Zeng K, Tong M, Lee AC, Ding J, Chen Q (2016) The reduction in circulating melatonin level may contribute to the pathogenesis of ovarian cancer: a retrospective study. J. Cancer 7: 831-836.
50. Chuffa LGA, Reiter RJ, Lupi LA (2017) Melatonin as a promising agent to treat ovarian cancer: molecular mechanisms. Carcinogenesis 38: 945-952.
51. Sánchez-Barceló EJ, Cos S, Fernández R, Mediavilla MD (2003) Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer 10: 153-159.
52. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ (2006). Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 30: 118-128.
53. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, Hauch A, Lundberg PW, Summers W, Yuan L, Frasch T, Blask DE (2015) Melatonin: an inhibitor of breast cancer. Endocr. Relat. Cancer 22: R183-204.
54. Schernhammer ES, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Chen WY (2012) A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. Cancer Causes Control 23: 609-616.
55. Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A, Alonso-González C (2005) Melatonin-estrogen interactions in breast cancer. J. Pineal Res. 38: 217-222.
56. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ (2008) Melatonin as a selective estrogen enzyme modulator. Curr. Cancer Drug Targets 8: 691-702.
57. Gonzalez A, Cos S, Martinez-Campa C, Alonso-Gonzalez C, Sanchez-Mateos S, Mediavilla MD, Sanchez-Barcelo EJ (2008) Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J. Pineal Res. 45: 86-92.
58. González A, Alvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ, Cos S (2010) In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. Curr. Cancer Drug Targets 10: 279-286.
59. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Alvarez-García V, Sánchez-Barceló EJ, Cos S (2009) Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br. J. Cancer 101: 1613-1619.
60. Wilson ST, Blask DE, Lemus-Wilson AM (1992) Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J. Clin. Endocrinol. Metab. 75: 669-670.
61. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ, Cos S (2005) Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 94: 249-254.
62. González-González A, Mediavilla MD, Sánchez-Barceló EJ (2018) Melatonin: A Molecule for Reducing Breast Cancer Risk. Molecules. 6: 23 (2) pii: E336. doi: 10.3390/molecules23020336.
63. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (2017) Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 1: CD004143. doi: 10.1002/14651858. CD004143.pub5.
64. Lobo RA (2017) Hormone-replacement therapy: current thinking. Nat. Rev. Endocrinol. 13: 220-231.
65. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalyses of data from 51 epidemiological studies of 52,705 women with breast cancer and 108, 411women without breast cancer. Lancet 350: 1047-1059.
66. Witt-Enderby PA, Davis VL, Lapinsky D (2014) Anti cancer tamoxifen melatonin hybrid ligand: Google Patents US8618083.
67. Neuhouser ML, Chlebowski RT, Anderson GL (2015) Association Between Obesity and Postmenopausal Breast Cancer Risk-Reply. JAMA Oncol. 1: 1171. doi: 10.1001/jamaoncol.2015.3313.
68. Sanchez-Mateos S, Alonso-Gonzalez C, Gonzalez A, Martinez-Campa CM, Mediavilla MD, Cos S, Sanchez-Barcelo EJ (2007) Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. Maturitas 58: 91-101.
69. Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A (2011) Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J. Pineal Res. 50: 171-182.
70. Cos S, Martínez-Campa C, Mediavilla MD, Sánchez-Barceló EJ (2005) Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J. Pineal Res. 38: 136-142.
71. Alvarez-García V, González A, Martínez-Campa C, Alonso-González C, Cos S (2013) Melatonin modulates aromatase activity and expression in endothelial cells. Oncol. Rep. 29: 2058-2064.
72. Gray JM, Rasanayagam S, Engel C & Rizzo J (2017) State of the evidence 2017: an update on the connection between breast cancer and the environment. Environ. Health 16: 94. doi: 10.1186/s12940-017-0287-4.
73. Cos S, Mediavilla D, Martínez-Campa C, González A, Alonso-González C, Sánchez-Barceló EJ (2006) Exposure to light-at-night increases the growth of DMBA-induced mammary adenocarcinomas in rats. Cancer Lett. 235: 266-271.
74. Wu J, Dauchy RT, Tirrell PC, Wu SS, Lynch DT, Jitawatanarat P, Burrington CM, Dauchy EM, Blask DE, Greene MW (2011) Light at night activates IGF-1R/PDK1 signaling and accelerates tumor growth in human breast cancer xenografts. Cancer Res. 71: 2622-2631.
75. Hansen J (2017) Night Shift Work and Risk of Breast Cancer. Curr. Environ. Health Rep. 4: 325-339.
76. Alonso-Gonzalez C, Mediavilla D, Martinez-Campa C, Gonzalez A, Cos S, Sanchez-Barcelo EJ (2008) Melatonin modulates the cadmium-induced expression of MT-2 and MT-1 metallothioneins in three lines of human tumor cells (MCF-7, MDA-MB-231 and HeLa). Toxicol. Lett. 181: 190-195.
77. Martínez-Campa CM, Alonso-González C, Mediavilla MD, Cos S, González A & Sanchez-Barcelo EJ (2008) Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett. 268: 272-277.
78. Martínez-Campa C, Alonso-González C, Mediavilla MD, Cos S, González A, Ramos S, Sánchez-Barceló EJ (2006) Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J. Pineal Res. 40: 291-296.
79. Alonso-González C, González A, Mazarrasa O, Güezmes A, Sánchez-Mateos S, Martínez-Campa C, Cos S, Sánchez-Barceló EJ, Mediavilla MD (2007) Melatonin prevents the estrogenic effects of sub-chronic administration of cadmium on mice mammary glands and uterus. J. Pineal Res. 42: 403-410.
80. Zhou L, Chen X, Yan J, Li M, Liu T, Zhu C, Pan G, Guo Q, Yang H, Pei M, He F (2017) Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS. Osteoporos. Int. 28: 3325-3337.
81. Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ (2010) Scientific basis for the potential use of melatonin in bone diseases: Osteoporosis and adolescent idiopathic scoliosis. J. Osteoporos. 2010: 830231. doi:10.4061/2010/ 830231.
82. Maria S, Witt-Enderby PA (2014) Melatonin effects on bone: Potential use for the prevention and treatment for osteopenia, osteoporosis, periodontal disease and for use in bone-grafting procedures. J. Pineal Res. 56: 115-125.
83. Amstrup AK, Sikjaer T, Mosekilde L, Rejnmark L (2013) Melatonin and the skeleton. Osteoporos. Int. 24: 2919-2927.
84. Kotlarczyk MP, Lassila HC, O'Neil CK, D'Amico F, Enderby LT, Witt-Enderby PA, Balk JL. (2012) Melatonin osteoporosis prevention study (MOPS): A randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J. Pineal Res. 52: 414-426.
85. Amstrup AK, Sikjaer T, Heickendorff L, Mosekilde L, Rejnmark L (2015) Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: A randomized controlled trial. J. Pineal Res. 59: 221-229.
86. Hasan M, Leak RK, Stratford RE, Zlotos DP, Witt-Enderby PA (2018) Drug conjugate, an emerging approach to treat breast cancer. Pharmacol. Res. Perspect. 6: e00417. doi: 10.1002/prp2.417.
87. Pourhanifeh MH, Mahdavinia M, Reiter RJ & Asemi Z (2019) Potential use of melatonin in skin cancer treatment: A review of current biological evidence. J. Cell Physiol. 234: 12142-12148.
88. Hao J, Fan W, Li Y, et al. (2019) Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits. J. Exp. Clin. Cancer Res. 38: 48. doi: 10.1186/s13046-019-1036-z.
89. Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, Meregalli S (1996) Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J. Pineal Res. 21: 239-242.
90. Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G (2002) A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha. In Vivo 16: 93-96.
91. Scheuer C, Pommergaard HC, Rosenberg J, Gögenur I (2016) Dose dependent sun protective effect of topical melatonin: A randomized, placebo-controlled, double-blind study. J. Dermatol. Sci. 84: 178-185.
92. Li T, Yang Z, Jiang S, Di W, Ma Z, Hu W, Chen F, Reiter RJ, Yang Y (2017) Melatonin: does it have utility in the treatment of haematological neoplasms? Br. J. Pharmacol. 175: 3251-3262.
93. Todisco M, Casaccia P, Rossi N (2001) Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin’s lymphomas at advanced stage: results of a phase II trial. Cancer Biother. Radiopharm. 16: 171-177.
94. Todisco M (2006). Relapse of high-grade non-Hodgkin’s lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH. Am. J. Ther. 13: 556-557.
95. Todisco M (2007). Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin. Am. J. Ther. 14: 113-115.
96. Todisco M (2009). Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. Cancer Biother. Radiopharm. 24: 353-355.
97. Tang YL, Sun X, Huang LB, Liu XJ, Qin G, Wang LN, Zhang XL, Ke ZY, Luo JS, Liang C, Peng CJ, Tang WY, Li Y, Huang W, Luo XQ, Deng W (2019) Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways. Cancer Lett. 443: 167-178.
98. González A, González-González A, Alonso-González C, Menéndez-Menéndez J, Martínez-Campa C, Cos S (2017) Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF. Oncol. Rep. 37: 2433-2440.
99. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53: 43-46.
100. Berk L, Berkey B, Rich T, Hrushesky W, Blask D, Gallagher M, Kudrimoti M, McGarry RC, Suh J, Mehta M (2007) Randomized phase II trial of high- dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int. J. Radiat. Oncol. Biol. Phys. 68: 852-857.
101. Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ, Yan X (2016) Melatonin as a potential anticarcinogen for non-small-cell lung cancer. Oncotarget 7: 46768-46784.
102. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G (2003) Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J. Pineal Res. 35: 12-15.
103. Norsa A, Martino V (2006) Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status. Cancer Biother. Radiopharm. 21: 68-73.
104. Norsa A, Martino V (2007) Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. Cancer Biother. Radiopharm. 22: 50-55.
105. Sookprasert A, Johns NP, Phunmanee A, Pongthai P, Cheawchanwattana A, Johns J, Konsil J, Plaimee P, Porasuphatana S, Jitpimolmard S (2014) Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial. Anticancer Res. 34: 7327-7337.
106. Ben-David MA, Elkayam R, Gelernter, Pfeffer RM (2016) melatonin for prevention of breast radiation dermatitis: a phase ii, prospective, double-blind randomized trial. Isr. Med. Assoc. J. 18: 188-192.
107. Bush SH, Lacaze-Masmonteil N, McNamara-Kilian MT, MacDonald AR, Tierney S, Momoli F, Agar M, Currow DC & Lawlor PG (2016) The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. Trials 17: 399 doi: 10.1186/s13063-016-1525-8.
108. Madsen MT, Hansen MV, Andersen LT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gögenur I (2016) Effect of melatonin on sleep in the perioperative period after breast cancer surgery: a randomized, double-blind, placebo-controlled trial. J. Clin. Sleep Med. 12: 225-233.
109. Innominato PF, Lim AS, Palesh O, Clemons M, Trudeau M, Eisen A, Wang C, Kiss A, Pritchard KI, Bjarnason GA (2016) The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer 24: 1097-1105.
110. Lund Rasmussen C, Klee Olsen M, Thit Johnsen A, Petersen MA, Lindholm H, Andersen L, Villadsen B, Groenvold M, Pedersen L (2015) Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial. Cancer 121: 3727-3736.
111. Hansen MV, Andersen LT, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gögenur I (2014) Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Res. Treat. 145: 683-695.
112. Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Schernhammer ES (2014) A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res. Treat. 145: 381-388.
113. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E (2013) Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J. Clin. Oncol. 31: 1271-1276.
114. Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G (2008) A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. In Vivo 22: 397-400.
115. Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F (2008) Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 28: 1377-1381.
116. Kayumov L, Lowe A, Rahman SA, Casper RF & Shapiro CM (2007) Prevention of melatonin suppression by nocturnal lighting: relevance to cancer. Eur. J. Cancer Prev. 16: 357-362.
117. Yin S, Hu SL, Shen G, Wang WD, Hu B, Xu WP, Wang H, Zhang Q (2006) The effect of amino acid nutritional support on serum tryptophan and melatonin in lung cancer patients receiving chemotherapy. Zhonghua Zhong Liu Za Zhi 28: 840-843.
118. Persson C, Glimelius B, Rönnelid J, Nygren P (2005) Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition 21: 170-178.
119. Carlson LE, Speca M, Patel KD, Goodey E (2004). Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 29: 448-474.
120. Lissoni P, Malugani F, Bukovec R, Bordin V, Perego M, Mengo S, Ardizzoia A, Tancini G (2003) Reduction of cisplatin-induced anemia by indole 5-methoxytryptamine in metastatic lung cancer patients. Neuro. Endocrinol. Lett. 24: 83-85.
121. Ghielmini M, Pagani O, de Jong J, Pampallona S, Conti A, Maestroni G, Sessa C, Cavalli F (1999) Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br. J. Cancer 80: 105810-105861.
122. Lissoni P, Tancini G, Paolorossi F, Mandalà M, Ardizzoia A, Malugani F, Giani L, Barni S (1999). Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J. Pineal Res. 26: 169-173.
123. Raschetti R (1999) Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trails. BMJ 318: 224-228.
124. Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F (1998) Biotherapy ith the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat. Immun. 16: 27-33.
125. Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A, Maestroni GJ (1997) A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J. Pineal Res. 23: 15-19.
126. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared radiotherapy alone. Oncology 53: 43-46.
2. Hardeland R (2008) Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol. Life Sci. 65 (13): 2001-2018.
3. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ (2012) Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin. Investig. Drugs 21: 819-831.
4. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Rueda N (2012) Breast cancer therapy based on melatonin. Recent Pat. Endocr. Metab. Immune Drug Discov. 6: 108-116.
5. Hill SM, Hill SM, Blask DE, Xiang S, Yuan L, Mao L, Dauchy RT, Dauchy EM, Frasch T, Duplesis T (2011) Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J. Mammary Gland Biol. Neoplasia 16: 235-245.
6. Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K (2017) Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int. J. Mol. Sci. 18 (4) pii: E843. doi: 10.3390/ijms18040843.
7. Talib WH (2018) Melatonin and cancer hallmarks. Molecules 23 (3) pii: E518. doi: 10.3390/molecules23030518.
8. Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Najafi M, Sahebkar A (2019) Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. J. Cell Physiol. 234: 5613-5627.
9. Najafi M, Salehi E, Farhood B, Nashtaei MS, Hashemi Goradel N, Khanlarkhani N, Namjoo Z, Mortezaee K (2019) Adjuvant chemotherapy with melatonin for targeting human cancers: A review. J. Cell Physiol. 234: 2356-2372.
10. Farhood B, Goradel NH, Mortezaee K, Khanlarkhani N, Salehi E, Nashtaei MS, Mirtavoos-Mahyari H, Motevaseli E, Shabeeb D, Musa AE, Najafi M (2019) Melatonin as an adjuvant in radiotherapy for radioprotection and radio-sensitization. Clin. Transl. Oncol. 21: 268-279.
11. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ (2010) Basic mechanisms involved in the anti-cancer effects of melatonin. Curr. Med. Chem. 17: 4462-4481.
12. Proietti S, Cucina A, Reiter RJ, Bizzarri M (2013) Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol. Life Sci. 70: 2139-2157.
13. Bondy SC, Campbell A (2018) Mechanisms Underlying Tumor Suppressive Properties of Melatonin. Int. J. Mol. Sci. 19 (8). pii: E2205. doi: 10.3390/ ijms19082205.
14. Lavastine L, Malméjac J (1939) Glande Pinéale. In: Traité de Physiologie Normale et Pathologique (Tome IV). Eds. Roger GH and Binet L. (Masson et Cie, Paris), pp 607-690.
15. Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ (2010) Clinical uses of melatonin: evaluation of human trials. Curr. Med. Chem. 17: 2070-2095.
16. Sánchez-Barceló EJ, Mediavilla MD, Reiter RJ (2011) Clinical uses of melatonin in pediatrics. Int. J. Pediatr. 2011: 892624. doi:10.1155/2011/892624.
17. Sanchez-Barcelo EJ, Rueda N, Mediavilla MD, Martinez-Cue C, Reiter RJ (2017) Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders. Curr. Med. Chem. 24: 3851-3878.
18. Cos S, Sánchez-Barceló EJ (2000). Melatonin and mammary pathological growth. Front. Neuroendocrinol. 21: 133-170.
19. Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C, Sánchez-Barceló EJ (2006). Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int. J. Cancer 118: 274-278.
20. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ (2010). Basic mechanisms involved in the anti-cancer effects of melatonin. Curr. Med. Chem. 17: 4462-4481.
21. Bizzarri M, Proietti S, Cucina A, Reiter RJ (2013) Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin. Ther. Targets 17: 1483-1496.
22. Onseng K, Johns NP, Khuayjarernpanishk T, Subongkot S, Priprem A, Hurst C, Johns J (2017) Beneficial effects of adjuvant melatonin in minimizing oral mucositis complications in head and neck cancer patients receiving concurrent chemoradiation. J. Altern. Complement Med. 23: 957-963.
23. Abdel Moneim AE, Guerra-Librero A, Florido J, Shen YQ, Fernández-Gil B, Acuña-Castroviejo D, Escames G (2017) Oral mucositis: melatonin gel an effective new treatment. Int. J. Mol. Sci. 18 (5) pii: E1003. doi: 10.3390/ijms18051003.
24. Su SC, Ho YC, Liu YF, Reiter RJ, Chou CH, Yeh CM, Lee HL, Chung WH, Hsieh MJ, Yang SF (2017) Association of melatonin membrane receptor1A/1B gene polymorphisms with the occurrence and metastasis of hepatocellular carcinoma. Oncotarget 8: 85655-85669.
25. Mortezaee K (2018) Human hepatocellular carcinoma: Protection by melatonin. J. Cell Physiol. 233: 6486-6508.
26. Prieto-Domínguez N, Ordóñez R, Fernández A, Méndez-Blanco C, Baulies A, Garcia-Ruiz C (2016) Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J. Pineal Res. 61: 396-407.
27. Prieto-Domínguez N, Méndez-Blanco C, Carbajo-Pescador S, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL (2017) Melatonin enhances enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy. Oncotarget 8: 91402-91414.
28. Lin S, Hoffmann K, Gao C, Petrulionis M, Herr I, Schemmer P (2017) Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. J. Pineal Res. 62 (3) doi: 10.1111/jpi.12398.
29. Yan JJ, Shen F, Wang K, Wu MC (2002) Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat Dis. Int. 1: 183-186.
30. Sakatani A, Sonohara F, Goel A (2019) Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis 40 (3): 422-431.doi.10.1093/carcin/bgy186.
31. Lee JH, Yun CW, Han YS, Kim S, Jeong D, Kwon HY, Kim H, Baek MJ, Lee SH (2018) Melatonin and 5-fluorouracil co-suppress colon cancer stem cells by regula-ting cellular prion protein-Oct4 axis. J. Pineal Res. 65: e12519. doi: 10.1111/jpi.12519.
32. Wang Q, Sun Z, Du L, Xu C, Wang Y, Yang B, He N, Wang J, Ji K, Liu Y, Liu Q. (2018) Melatonin sensitizes human colorectal cancer cells to γ-ray ionizing radiation in vitro and in vivo. Int. J. Mol. Sci. 19: pii: E3974. doi: 10.3390/ijms19123974.
33. Lee JH, Yoon YM, Han YS, Yun CW, Lee SH (2018) Melatonin promotes apoptosis of oxaliplatin-resistant colorectal cancer cells through inhibition of cellular prion protein. Anticancer Res. 38: 1993-2000.
34. Wei JY, Li WM, Zhou LL, Lu QN, He W (2015) Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. J. Pineal Res. 58: 429-438.
35. Yun CW, Kim S, Lee JH, Lee SH (2018) Melatonin promotes apoptosis of colorectal cancer cells via superoxide-mediated ER stress by inhibiting cellular prion protein expression. Anticancer Res. 38: 3951-3960.
36. Lissoni P (2007). Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol. Biol. 55: 201-204.
37. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P (2003) Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 23: 1951-1954.
38. Asghari MH, Moloudizargari M, Ghobadi E, Fallah M, Abdollahi M (2017) Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer. Life Sci. 185: 38-45.
39. Song J, Ma SJ, Luo JH, Zhang H, Wang RX, Liu H, Li L, Zhang ZG, Zhou RX (2018) Melatonin induces the apoptosis and inhibits the proliferation of human gastric cancer cells via blockade of the AKT/MDM2 pathway. Oncol. Rep. 39: 1975-1983.
40. Michl P, Gress TM (2013) Current concepts and novel targets in advanced pancreatic cancer. Gut 62: 317-326.
41. Jaworek J, Leja-Szpak A, Nawrot-Porąbka K, Szklarczyk J, Kot M, Pierzchalski P, Góralska M (2017) Effects of melatonin and its analogues on pancreatic inflammation, enzyme secretion, and tumorigenesis. Int. J. Mol. Sci. 18: pii: E1014. doi: 10.3390/ijms18051014.
42. Tamtaji OR, Mirhosseini N, Reiter RJ, Behnamfar M, Asemi Z (2019) Melatonin and pancreatic cancer: Current knowledge and future perspectives. J. Cell Physiol. 234: 5372-5378.
43. Li W, Wu J, Li Z, Zhou Z, Zheng C, Lin L, Tan B, Huang M, Fan M (2016) Melatonin induces cell apoptosis in Mia PaCa-2 cells via the suppression of nuclear factor-κB and activation of ERK and JNK: A novel therapeutic implication for pancreatic cancer. Oncol. Rep. 36: 2861-2867.
44. Fang Z, Jung KH, Yan HH, Kim SJ, Rumman M, Park JH, Han B, Lee JE, Kang YW, Lim JH, Hong SS (2018) Melatonin synergizes with sorafenib to suppress pancreatic cancer via melatonin receptor and PDGFR-β/STAT3 pathway. Cell Physiol. Biochem. 47: 1751-1768.
45. Sigurdardottir LG, Markt SC, Rider JR, et al. (2015) Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. Eur. Urol. 67: 191-194.
46. Tay SY, Huang SP, Bao BY, Wu MT (2016) Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study. Sci. Rep. 6: 29606. doi: 10.1038/srep29606.
47. Liu VWS, Yau WL, Tam CW, Yao KM & Shiu SYW (2017) Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-κB) activation and NF-κB activator-induced AR-V7 expression in prostate cancer cells: potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) therapy. Int. J. Mol. Sci. 18 (6): 1130. doi: 10.3390/ijms18061130.
48. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E (2012) Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials. Integr. Cancer Ther. 11: 293-303.
49. Zhao M, Wan J, Zeng K, Tong M, Lee AC, Ding J, Chen Q (2016) The reduction in circulating melatonin level may contribute to the pathogenesis of ovarian cancer: a retrospective study. J. Cancer 7: 831-836.
50. Chuffa LGA, Reiter RJ, Lupi LA (2017) Melatonin as a promising agent to treat ovarian cancer: molecular mechanisms. Carcinogenesis 38: 945-952.
51. Sánchez-Barceló EJ, Cos S, Fernández R, Mediavilla MD (2003) Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer 10: 153-159.
52. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ (2006). Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 30: 118-128.
53. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, Hauch A, Lundberg PW, Summers W, Yuan L, Frasch T, Blask DE (2015) Melatonin: an inhibitor of breast cancer. Endocr. Relat. Cancer 22: R183-204.
54. Schernhammer ES, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Chen WY (2012) A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. Cancer Causes Control 23: 609-616.
55. Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A, Alonso-González C (2005) Melatonin-estrogen interactions in breast cancer. J. Pineal Res. 38: 217-222.
56. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ (2008) Melatonin as a selective estrogen enzyme modulator. Curr. Cancer Drug Targets 8: 691-702.
57. Gonzalez A, Cos S, Martinez-Campa C, Alonso-Gonzalez C, Sanchez-Mateos S, Mediavilla MD, Sanchez-Barcelo EJ (2008) Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J. Pineal Res. 45: 86-92.
58. González A, Alvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ, Cos S (2010) In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. Curr. Cancer Drug Targets 10: 279-286.
59. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Alvarez-García V, Sánchez-Barceló EJ, Cos S (2009) Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br. J. Cancer 101: 1613-1619.
60. Wilson ST, Blask DE, Lemus-Wilson AM (1992) Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J. Clin. Endocrinol. Metab. 75: 669-670.
61. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ, Cos S (2005) Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 94: 249-254.
62. González-González A, Mediavilla MD, Sánchez-Barceló EJ (2018) Melatonin: A Molecule for Reducing Breast Cancer Risk. Molecules. 6: 23 (2) pii: E336. doi: 10.3390/molecules23020336.
63. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (2017) Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 1: CD004143. doi: 10.1002/14651858. CD004143.pub5.
64. Lobo RA (2017) Hormone-replacement therapy: current thinking. Nat. Rev. Endocrinol. 13: 220-231.
65. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalyses of data from 51 epidemiological studies of 52,705 women with breast cancer and 108, 411women without breast cancer. Lancet 350: 1047-1059.
66. Witt-Enderby PA, Davis VL, Lapinsky D (2014) Anti cancer tamoxifen melatonin hybrid ligand: Google Patents US8618083.
67. Neuhouser ML, Chlebowski RT, Anderson GL (2015) Association Between Obesity and Postmenopausal Breast Cancer Risk-Reply. JAMA Oncol. 1: 1171. doi: 10.1001/jamaoncol.2015.3313.
68. Sanchez-Mateos S, Alonso-Gonzalez C, Gonzalez A, Martinez-Campa CM, Mediavilla MD, Cos S, Sanchez-Barcelo EJ (2007) Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. Maturitas 58: 91-101.
69. Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A (2011) Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J. Pineal Res. 50: 171-182.
70. Cos S, Martínez-Campa C, Mediavilla MD, Sánchez-Barceló EJ (2005) Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J. Pineal Res. 38: 136-142.
71. Alvarez-García V, González A, Martínez-Campa C, Alonso-González C, Cos S (2013) Melatonin modulates aromatase activity and expression in endothelial cells. Oncol. Rep. 29: 2058-2064.
72. Gray JM, Rasanayagam S, Engel C & Rizzo J (2017) State of the evidence 2017: an update on the connection between breast cancer and the environment. Environ. Health 16: 94. doi: 10.1186/s12940-017-0287-4.
73. Cos S, Mediavilla D, Martínez-Campa C, González A, Alonso-González C, Sánchez-Barceló EJ (2006) Exposure to light-at-night increases the growth of DMBA-induced mammary adenocarcinomas in rats. Cancer Lett. 235: 266-271.
74. Wu J, Dauchy RT, Tirrell PC, Wu SS, Lynch DT, Jitawatanarat P, Burrington CM, Dauchy EM, Blask DE, Greene MW (2011) Light at night activates IGF-1R/PDK1 signaling and accelerates tumor growth in human breast cancer xenografts. Cancer Res. 71: 2622-2631.
75. Hansen J (2017) Night Shift Work and Risk of Breast Cancer. Curr. Environ. Health Rep. 4: 325-339.
76. Alonso-Gonzalez C, Mediavilla D, Martinez-Campa C, Gonzalez A, Cos S, Sanchez-Barcelo EJ (2008) Melatonin modulates the cadmium-induced expression of MT-2 and MT-1 metallothioneins in three lines of human tumor cells (MCF-7, MDA-MB-231 and HeLa). Toxicol. Lett. 181: 190-195.
77. Martínez-Campa CM, Alonso-González C, Mediavilla MD, Cos S, González A & Sanchez-Barcelo EJ (2008) Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett. 268: 272-277.
78. Martínez-Campa C, Alonso-González C, Mediavilla MD, Cos S, González A, Ramos S, Sánchez-Barceló EJ (2006) Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J. Pineal Res. 40: 291-296.
79. Alonso-González C, González A, Mazarrasa O, Güezmes A, Sánchez-Mateos S, Martínez-Campa C, Cos S, Sánchez-Barceló EJ, Mediavilla MD (2007) Melatonin prevents the estrogenic effects of sub-chronic administration of cadmium on mice mammary glands and uterus. J. Pineal Res. 42: 403-410.
80. Zhou L, Chen X, Yan J, Li M, Liu T, Zhu C, Pan G, Guo Q, Yang H, Pei M, He F (2017) Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS. Osteoporos. Int. 28: 3325-3337.
81. Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ (2010) Scientific basis for the potential use of melatonin in bone diseases: Osteoporosis and adolescent idiopathic scoliosis. J. Osteoporos. 2010: 830231. doi:10.4061/2010/ 830231.
82. Maria S, Witt-Enderby PA (2014) Melatonin effects on bone: Potential use for the prevention and treatment for osteopenia, osteoporosis, periodontal disease and for use in bone-grafting procedures. J. Pineal Res. 56: 115-125.
83. Amstrup AK, Sikjaer T, Mosekilde L, Rejnmark L (2013) Melatonin and the skeleton. Osteoporos. Int. 24: 2919-2927.
84. Kotlarczyk MP, Lassila HC, O'Neil CK, D'Amico F, Enderby LT, Witt-Enderby PA, Balk JL. (2012) Melatonin osteoporosis prevention study (MOPS): A randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J. Pineal Res. 52: 414-426.
85. Amstrup AK, Sikjaer T, Heickendorff L, Mosekilde L, Rejnmark L (2015) Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: A randomized controlled trial. J. Pineal Res. 59: 221-229.
86. Hasan M, Leak RK, Stratford RE, Zlotos DP, Witt-Enderby PA (2018) Drug conjugate, an emerging approach to treat breast cancer. Pharmacol. Res. Perspect. 6: e00417. doi: 10.1002/prp2.417.
87. Pourhanifeh MH, Mahdavinia M, Reiter RJ & Asemi Z (2019) Potential use of melatonin in skin cancer treatment: A review of current biological evidence. J. Cell Physiol. 234: 12142-12148.
88. Hao J, Fan W, Li Y, et al. (2019) Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits. J. Exp. Clin. Cancer Res. 38: 48. doi: 10.1186/s13046-019-1036-z.
89. Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, Meregalli S (1996) Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J. Pineal Res. 21: 239-242.
90. Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G (2002) A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha. In Vivo 16: 93-96.
91. Scheuer C, Pommergaard HC, Rosenberg J, Gögenur I (2016) Dose dependent sun protective effect of topical melatonin: A randomized, placebo-controlled, double-blind study. J. Dermatol. Sci. 84: 178-185.
92. Li T, Yang Z, Jiang S, Di W, Ma Z, Hu W, Chen F, Reiter RJ, Yang Y (2017) Melatonin: does it have utility in the treatment of haematological neoplasms? Br. J. Pharmacol. 175: 3251-3262.
93. Todisco M, Casaccia P, Rossi N (2001) Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin’s lymphomas at advanced stage: results of a phase II trial. Cancer Biother. Radiopharm. 16: 171-177.
94. Todisco M (2006). Relapse of high-grade non-Hodgkin’s lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH. Am. J. Ther. 13: 556-557.
95. Todisco M (2007). Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin. Am. J. Ther. 14: 113-115.
96. Todisco M (2009). Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. Cancer Biother. Radiopharm. 24: 353-355.
97. Tang YL, Sun X, Huang LB, Liu XJ, Qin G, Wang LN, Zhang XL, Ke ZY, Luo JS, Liang C, Peng CJ, Tang WY, Li Y, Huang W, Luo XQ, Deng W (2019) Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways. Cancer Lett. 443: 167-178.
98. González A, González-González A, Alonso-González C, Menéndez-Menéndez J, Martínez-Campa C, Cos S (2017) Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF. Oncol. Rep. 37: 2433-2440.
99. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53: 43-46.
100. Berk L, Berkey B, Rich T, Hrushesky W, Blask D, Gallagher M, Kudrimoti M, McGarry RC, Suh J, Mehta M (2007) Randomized phase II trial of high- dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int. J. Radiat. Oncol. Biol. Phys. 68: 852-857.
101. Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ, Yan X (2016) Melatonin as a potential anticarcinogen for non-small-cell lung cancer. Oncotarget 7: 46768-46784.
102. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G (2003) Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J. Pineal Res. 35: 12-15.
103. Norsa A, Martino V (2006) Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status. Cancer Biother. Radiopharm. 21: 68-73.
104. Norsa A, Martino V (2007) Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. Cancer Biother. Radiopharm. 22: 50-55.
105. Sookprasert A, Johns NP, Phunmanee A, Pongthai P, Cheawchanwattana A, Johns J, Konsil J, Plaimee P, Porasuphatana S, Jitpimolmard S (2014) Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial. Anticancer Res. 34: 7327-7337.
106. Ben-David MA, Elkayam R, Gelernter, Pfeffer RM (2016) melatonin for prevention of breast radiation dermatitis: a phase ii, prospective, double-blind randomized trial. Isr. Med. Assoc. J. 18: 188-192.
107. Bush SH, Lacaze-Masmonteil N, McNamara-Kilian MT, MacDonald AR, Tierney S, Momoli F, Agar M, Currow DC & Lawlor PG (2016) The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. Trials 17: 399 doi: 10.1186/s13063-016-1525-8.
108. Madsen MT, Hansen MV, Andersen LT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gögenur I (2016) Effect of melatonin on sleep in the perioperative period after breast cancer surgery: a randomized, double-blind, placebo-controlled trial. J. Clin. Sleep Med. 12: 225-233.
109. Innominato PF, Lim AS, Palesh O, Clemons M, Trudeau M, Eisen A, Wang C, Kiss A, Pritchard KI, Bjarnason GA (2016) The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer 24: 1097-1105.
110. Lund Rasmussen C, Klee Olsen M, Thit Johnsen A, Petersen MA, Lindholm H, Andersen L, Villadsen B, Groenvold M, Pedersen L (2015) Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial. Cancer 121: 3727-3736.
111. Hansen MV, Andersen LT, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gögenur I (2014) Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Res. Treat. 145: 683-695.
112. Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Schernhammer ES (2014) A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res. Treat. 145: 381-388.
113. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E (2013) Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J. Clin. Oncol. 31: 1271-1276.
114. Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G (2008) A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. In Vivo 22: 397-400.
115. Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F (2008) Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 28: 1377-1381.
116. Kayumov L, Lowe A, Rahman SA, Casper RF & Shapiro CM (2007) Prevention of melatonin suppression by nocturnal lighting: relevance to cancer. Eur. J. Cancer Prev. 16: 357-362.
117. Yin S, Hu SL, Shen G, Wang WD, Hu B, Xu WP, Wang H, Zhang Q (2006) The effect of amino acid nutritional support on serum tryptophan and melatonin in lung cancer patients receiving chemotherapy. Zhonghua Zhong Liu Za Zhi 28: 840-843.
118. Persson C, Glimelius B, Rönnelid J, Nygren P (2005) Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition 21: 170-178.
119. Carlson LE, Speca M, Patel KD, Goodey E (2004). Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 29: 448-474.
120. Lissoni P, Malugani F, Bukovec R, Bordin V, Perego M, Mengo S, Ardizzoia A, Tancini G (2003) Reduction of cisplatin-induced anemia by indole 5-methoxytryptamine in metastatic lung cancer patients. Neuro. Endocrinol. Lett. 24: 83-85.
121. Ghielmini M, Pagani O, de Jong J, Pampallona S, Conti A, Maestroni G, Sessa C, Cavalli F (1999) Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br. J. Cancer 80: 105810-105861.
122. Lissoni P, Tancini G, Paolorossi F, Mandalà M, Ardizzoia A, Malugani F, Giani L, Barni S (1999). Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J. Pineal Res. 26: 169-173.
123. Raschetti R (1999) Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trails. BMJ 318: 224-228.
124. Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F (1998) Biotherapy ith the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat. Immun. 16: 27-33.
125. Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A, Maestroni GJ (1997) A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J. Pineal Res. 23: 15-19.
126. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared radiotherapy alone. Oncology 53: 43-46.
Published
2019-06-12
How to Cite
[1]
González González, A., Rueda Revilla, N. and Sánchez-Barceló, E. 2019. Clinical uses of melatonin: evaluation of human trials on cancer treatment. Melatonin Research. 2, 2 (Jun. 2019), 47-69. DOI:https://doi.org/https://doi.org/10.32794/mr11250021.
Section
Reviews
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Melatonin Res., copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper credit.
In exceptional circumstances articles may be licensed differently. If you have specific condition (such as one linked to funding) that does not allow this license, please mention this to the editorial office of the journal at submission. Exceptions will be granted at the discretion of the publisher.
